The stock of uniQure N.V. (NASDAQ:QURE) last traded at $21.32, up 2.25% from the previous session.
As we calculate the median target price by taking the range between a high of $90.00 and a low of $24.00, we find $53.00. Given the previous closing price of $20.85, this indicates a potential upside of 154.2 percent. QURE stock price is now -1.63% away from the 50-day moving average and 4.37% away from the 200-day moving average. The market capitalization of the company currently stands at $1.02B.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Brokers who have rated the stock have averaged $52.41 as their price target over the next twelve months.
With the price target maintained at $40, UBS recently Upgraded its rating from Neutral to Buy for uniQure N.V. (NASDAQ: QURE). On June 15, 2021, BTIG Research recently initiated its ‘Buy’ rating on the stock quoting a target price of $46, while ‘UBS’ rates the stock as ‘Neutral’.
In other news, Kapusta Matthew C, CEO, Managing Director sold 5,021 shares of the company’s stock on Feb 28. The stock was sold for $104,939 at an average price of $20.90. Upon completion of the transaction, the CEO, Managing Director now directly owns 471,264 shares in the company, valued at $10.05 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Feb 28, Director Gut Robert sold 1,431 shares of the business’s stock. A total of $30,280 was realized by selling the stock at an average price of $21.16. This leaves the insider owning 42,197 shares of the company worth $0.9 million. Insiders disposed of 91,322 shares of company stock worth roughly $1.95 million over the past 1 year. A total of 1.70% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in QURE stock. A new stake in uniQure N.V. shares was purchased by BIOIMPACT CAPITAL LLC during the first quarter worth $20,040,000. MILLENNIUM MANAGEMENT LLC invested $15,949,000 in shares of QURE during the first quarter. In the first quarter, LORD, ABBETT & CO. LLC acquired a new stake in uniQure N.V. valued at approximately $3,292,000. HRT FINANCIAL LP acquired a new stake in QURE for approximately $2,710,000. SILVERCREST ASSET MANAGEMENT GROUP LLC purchased a new stake in QURE valued at around $2,141,000 in the second quarter. In total, there are 260 active investors with 92.30% ownership of the company’s stock.
With an opening price of $20.85 on Tuesday morning, uniQure N.V. (NASDAQ: QURE) set off the trading day. During the past 12 months, uniQure N.V. has had a low of $12.52 and a high of $28.25. As of last week, the company has a debt-to-equity ratio of 0.22, a current ratio of 6.30, and a quick ratio of 6.20. The fifty day moving average price for QURE is $21.67 and a two-hundred day moving average price translates $20.43 for the stock.
The latest earnings results from uniQure N.V. (NASDAQ: QURE) was released for Sep, 2022. According to the Biotechnology Company, earnings per share came in at -$1.02, beating analysts’ expectations of -$1.16 by 0.14. This compares to $0.23 EPS in the same period last year. For the current quarter, analysts expect QURE to generate $22M in revenue.
uniQure N.V.(QURE) Company Profile
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington’s disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson’s disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer’s disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Leave a Reply